NPIL–Reckitt JV under strain - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

NPIL–Reckitt JV under strain

Mar 27, 2000

Reckitt Benckiser, the $ 3.1 bn parent of Reckitt & Colman (R & C) India is reviewing the company’s joint venture (JV) with Nicholas Piramal (NPIL). R & C India had transferred two of its over the counter pharmaceutical brands Dettol and Dispirin to the joint venture in which it held 20% while 40% each was held by its parent and NPIL respectively.

The transfer of the brands had hit the valuation of the listed company since the transfers were made without any consideration apart from giving R & C a 20% stake in the JV. Besides, it was also announced at the time of setting up of the venture that henceforth the pharmaceutical products of the parent would be introduced through the JV and not through R & C India.

The joint venture had a turnover of Rs 2.12 bn in the first nine months of FY 2000, a 9% growth over the previous year. This in fact is slightly over the overall formulations growth of 7% shown by the pharmaceutical industry. Companies such as Glaxo India that have a very high percentage of prescription brands have also grown by 9%. It is quite possible that had the brand remained with the listed company it would have grown equally if not more.

However, the impact of the reported review on the stocks of both R & C and NPIL is still not clear since an announcement on the future of the brands is still awaited. If the joint venture splits and the brands return to the R & C fold it would be a definite positive for the stock. (R & C ‘s parent had earlier requested the FIPB for setting up a 100% subsidiary which was rejected.)

NPIL has built a network of relationships with more than half a dozen alliances and joint ventures currently in operation. The importance of continuity in these relationships cannot be overstated. If for whatsoever reason relationships turn sour, it could damage NPIL’s value in the future.

Equitymaster requests your view! Post a comment on "NPIL–Reckitt JV under strain". Click here!


More Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Mar 7, 2019 10:55 AM


  • Track your investment in RECKITT BENCKISER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks